Related conditions

Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low MultipleSolitary Plasmacytomas Harboring a 17p Deletion. Kitamura H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.9446-17. [Epub ahead of print]. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic…

Details

General

Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. Postmus D et al. Oncologist. 2017 Oct 27. pii: theoncologist.2017-0257. doi: 10.1634/theoncologist.2017-0257. [Epub ahead of print]. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Jimenez-Zepeda VH et al. Leuk Lymphoma. 2017 Nov 21:1-7. doi:…

Details

Emerging treatments

CD38 bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B cell malignancies. Green DJ et al.Blood. 2017 Nov 20. pii: blood-2017-09-807610. doi: 10.1182/blood-2017-09-807610. [Epub ahead of print]. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Prabhu VV et al. Cell Cycle. 2017 Nov 20:1-29. doi: 10.1080/15384101.2017.1403689. [Epub ahead of print]. A review discussing elotuzumab…

Details

Diagnostic techniques and prognostic indicators

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. Bossuyt X et al.Leukemia. 2017 Nov 20. doi: 10.1038/leu.2017.335. [Epub ahead of print]. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. Cetin AE et al. Nat Commun. 2017 Nov 20;8(1):1613. doi: 10.1038/s41467-017-01593-2. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma. Dalla Palma B et al. Br J Haematol. 2017 Nov…

Details

Current treatments

Final analysis of survival outcomes in the randomized phase 3 FIRST trial. Facon T et al. Blood. 2017 Nov 17. pii: blood-2017-07-795047. doi: 10.1182/blood-2017-07-795047. [Epub ahead of print]. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Sivaraj D et al. Bone Marrow Transplant. 2017 Oct 30. doi: 10.1038/bmt.2017.208. [Epub ahead of print]. An overview of the…

Details

Complications of myeloma and its treatments

Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. Maki H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.8886-17. [Epub ahead of print]. Severe Hypoglycemia Caused by Lenalidomide. Przybylski DJ et al. Pharmacotherapy. 2017 Nov 20. doi: 10.1002/phar.2061. [Epub ahead of print]. Cardiovascular complications of multiple myeloma in the elderly. Mathur P et al. Expert Rev Cardiovasc Ther. 2017 Nov…

Details

Biology and genetics

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Botta C et al. Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.336. [Epub ahead of print]. Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma. Gullà A et al.Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.334. [Epub ahead of print]. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences…

Details